- Policy
- HIRA in final stages of preparing expense report survey
- by Lee, Tak-Sun Apr 5, 2024 05:43am
- The Health Insurance Review and Assessment Service is busy preparing a survey and public disclosure of the expenditure reports on economic benefits pharmaceutical companies and medical device companies provided to doctors and pharmacists. As the data submitted by pharmaceutical companies through the survey will be subject to public dis
- Policy
- Trajenta generics enter reimbursement pricing…
- by Lee, Tak-Sun Apr 5, 2024 05:43am
- The generic version of Trajenta (linagliptin), a DPP-4 inhibitor class, has applied for reimbursement pricing ahead of its launch in June. This year, generic market is drawing attention to Trajenta. With the exclusive rights for Trajenta is set to expire, after Forxiga and Januvia last year, the diabetes market is expected to see new c
- Company
- Boryung speeds up Lenvima patent challenge
- by Heo sung-kyu Apr 4, 2024 06:00am
- Boryung's challenge against Eisai’s blockbuster anticancer drug Lenvima is gathering pace. As the only domestic pharmaceutical company to continue the patent challenge, Boryung’s journey has passed the 70% mark. With only one patent remaining, expectations of the company’s launch of the Lenvima generic in 2025 are rising. According to i
- Company
- Enhertu lands in general hospitals in KOR after reimb
- by Eo, Yun-Ho Apr 4, 2024 06:00am
- Hospitals in Korea are busy preparing a prescription environment for the reimbursed Enhertu. According to industry sources, Daiichi Sankyo and AstraZeneca Korea’s antibody-drug conjugate (ADC) for HER2-positive breast cancer, Enhertu (trastuzumab deruxtecan) has passed the drug committee (DC) review of 46 medical institutions in Korea,
- Policy
- Eye drops late to submit test results pass reivew
- by Lee, Hye-Kyung Apr 4, 2024 05:59am
- Amid the ongoing equivalence reevaluations being conducted on eye drops, products that received dispositions for failing to submit equivalence data in time received a final compliant decision. The Ministry of Food and Drug Safety (MFDS) released the results of the ‘2022 drug equivalence reevaluation’ that contained such results on the 3rd.
- Policy
- K-CAB is in talks to extend refund-type PVA
- by Lee, Tak-Sun Apr 4, 2024 05:59am
- HK inno.N is in talks with the National Health Insurance Service (NHIS) to extend the refund-type price-volume agreement (PVA) for K-CAB (tegoprazan), a drug developed in Korea for gastroesophageal reflux disease. K-CAB is the only drug under the refund-type price-volume agreement (PVA). Since its release in 2019, K-CAB’s claim amount
- Company
- AbTis-Progen signs MOU to develop bispecific antibody ADC
- by Son, Hyung-Min Apr 3, 2024 05:51am
- AbTis, Dong-A ST’s affiliate specializing in ADC, announced on April 1 that it has signed a memorandum of understanding (MOU) with Progen to develop a bispecific antibody-drug conjugate (BsADC) to treat autoimmune diseases. The MOU will leverage the two companies’ proprietary platform technologies - AbTis’ AbClick and Progen's NTIG.
- Company
- Hanmi files phase 1 FDA IND for their next-gen obesity drug
- by Son, Hyung-Min Apr 3, 2024 05:50am
- Hanmi Pharmaceutical announced on the 1st that it submitted an investigational new drug (IND) to the U.S. FDA on March 29 for its triple-agonist (HM15275), a next-generation obesity drug. Its IND includes a trial goal to assess drug tolerance, pharmacokinetics, and pharmacodynamics of HM15275 in healthy adults and patients with obesity.
- Company
- Pharmas face sales challenges and rebate monitoring
- by Son, Hyung-Min Apr 3, 2024 05:50am
- As the ongoing feud between the medical community and the government over the medical school quota continues, the pharmaceutical industry faces the full impact. In addition to major hospitals, outpatient clinics have shortened working hours, making it difficult for some pharmaceutical company employees even to meet medical professionals. Sales a
- Company
- Pfizer expands co-marketing partnership deals
- by Son, Hyung-Min Apr 3, 2024 05:50am
- Pfizer Korea will co-market 2 blockbuster autoimmune disease drugs with a local drug distributor Hanlim MS. Pfizer has signed copromotion deals with Jeil Pharmaceutical, Donghwa Pharm, and Chong Ku Dang, but this is the first time the company has signed a co-marketing partnership deal with Hanlim MS. The company explained that it decided to part
